Literature DB >> 31787823

Head-Up Tilt Test in Risk Stratification of Patients with Hypertrophic Cardiomyopathy.

Hana Sediva1, T Hnat1, J Bonaventura1, J Slesarenko1, J Veselka1.   

Abstract

Conflicting results have been published considering the role of head-up tilt test (HUTT) positivity as a prognostic factor in patients with hypertrophic cardiomyopathy (HCM). The relationship between HCM patients' genotype and their HUTT results has not been previously reported. The aim of this study was to evaluate patients with HCM and their HUTT results in regard to its value for outcome prediction and to investigate the relation of patients' genotype and their HUTT results. Seventy-four (51 ± 15 years; 42% women; median follow-up 72 months) HCM patients were divided into two groups based on their HUTT results and were retrospectively analyzed. In 67 (90.5%) subjects included in the analysis, next-generation sequencing-based genomic testing was performed. A composite end point of unexplained syncope, heart failure hospitalization, and death was defined. A total of 14 patients (18.9%) had positive HUTT (HUTT+), whereas 60 (81.1%) had negative HUTT (HUTT-). Except for the New York Heart Association functional class ( p  = 0.01), both groups had similar characteristics. Positive genotype was evenly distributed between the two groups. Composite end point occurred in 5 patients (35.7%) in HUTT+ group versus 14 (23.3%) patients in HUTT- group ( p  = 0.33). We did not find a relationship between HUTT results and long-term outcome. We found no association between HUTT results and genotype. © Thieme Medical Publishers.

Entities:  

Keywords:  HCM; HOCM; abnormal baroreflex; genotype; head-up tilt test; hypertrophic cardiomyopathy; hypertrophic obstructive cardiomyopathy

Year:  2019        PMID: 31787823      PMCID: PMC6882664          DOI: 10.1055/s-0039-1688983

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  23 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

2.  Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy.

Authors:  N Sadoul; K Prasad; P M Elliott; S Bannerjee; M P Frenneaux; W J McKenna
Journal:  Circulation       Date:  1997-11-04       Impact factor: 29.690

Review 3.  New Developments in Hypertrophic Cardiomyopathy.

Authors:  Robert M Cooper; Claire E Raphael; Max Liebregts; Nandan S Anavekar; Josef Veselka
Journal:  Can J Cardiol       Date:  2017-07-20       Impact factor: 5.223

4.  Assessment of the diagnostic value of head-up tilt testing in the evaluation of syncope in hypertrophic cardiomyopathy.

Authors:  J F Sneddon; A Slade; H Seo; A J Camm; W J McKenna
Journal:  Am J Cardiol       Date:  1994-03-15       Impact factor: 2.778

5.  Diagnosis of neurally mediated syncope at initial evaluation and with tilt table testing compared with that revealed by prolonged ECG monitoring. An analysis from the Third International Study on Syncope of Uncertain Etiology (ISSUE-3).

Authors:  Andrea Ungar; Paolo Sgobino; Vitantonio Russo; Elena Vitale; Richard Sutton; Donato Melissano; Xulio Beiras; Nicola Bottoni; Hans H Ebert; Michele Gulizia; Marcella Jorfida; Angel Moya; Dietrich Andresen; Nicoletta Grovale; Michele Brignole
Journal:  Heart       Date:  2013-10-23       Impact factor: 5.994

Review 6.  Hypertrophic obstructive cardiomyopathy.

Authors:  Josef Veselka; Nandan S Anavekar; Philippe Charron
Journal:  Lancet       Date:  2016-11-30       Impact factor: 79.321

7.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

8.  Comparison of hemodynamic adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncope.

Authors:  Fiore Manganelli; Sandro Betocchi; Quirino Ciampi; Giovanni Storto; Maria Angela Losi; Anna Violante; Carlo Briguori; Carlo Gabriele Tocchetti; Raffaella Lombardi; Alberto Cuocolo; Massimo Chiariello
Journal:  Am J Cardiol       Date:  2002-06-15       Impact factor: 2.778

9.  Syncope and risk of sudden death in hypertrophic cardiomyopathy.

Authors:  Paolo Spirito; Camillo Autore; Claudio Rapezzi; Paola Bernabò; Roberto Badagliacca; Martin S Maron; Sergio Bongioanni; Fabio Coccolo; N A Mark Estes; Caterina S Barillà; Elena Biagini; Giovanni Quarta; Maria Rosa Conte; Paolo Bruzzi; Barry J Maron
Journal:  Circulation       Date:  2009-03-23       Impact factor: 29.690

10.  The utility of the Mayo Score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy.

Authors:  Jiří Bonaventura; Patricia Norambuena; Pavol Tomašov; Denisa Jindrová; Hana Šedivá; Milan Macek; Josef Veselka
Journal:  Arch Med Sci       Date:  2018-10-08       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.